Updated results of the first in man evaluation of the histone deacetylase (HDAC) inhibitor, PXD101 in cancer patients (pts).

被引：0
|
作者：
de Bono, JS
Steele, N
Vidal, L
Reid, A
Marriott, C
Tjornelund, J
Shaw, H
Plumb, J
Molife, R
Morrison, R
Fong, P
Buhl-Jensen, P
Rasmussen, A
Evans, TRJ
机构：
[1] Royal Marsden NHS Trust, Sutton, Surrey, England
[2] Beatson Oncol Ctr, Glasgow, Lanark, Scotland
[3] TopoTargets, Copenhagen, Denmark
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9121S / 9121S
页数：1
相关论文
共 50 条
  • [31] Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
    Ramalingam, Suresh S.
    Belani, Chandra. P.
    Ruel, Christopher
    Frankel, Paul
    Gitlitz, Barbara
    Koczywas, Marianna
    Espinoza-Delgado, Igor
    Gandara, David
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (01) : 97 - 101
  • [32] Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells
    S. H. Kim
    J. G. Kang
    C. S. Kim
    S.-H. Ihm
    M. G. Choi
    H. J. Yoo
    S. J. Lee
    Journal of Endocrinological Investigation, 2018, 41 : 677 - 689
  • [33] Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells
    Kim, S. H.
    Kang, J. G.
    Kim, C. S.
    Ihm, S-H
    Choi, M. G.
    Yoo, H. J.
    Lee, S. J.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2018, 41 (06) : 677 - 689
  • [34] Combination of the proteasome inhibitor bortezomib and a histone deacetylase inhibitor PXD101 results in synergistic inhibition of osteoclastogenesis and significantly stronger inhibition of multiple myeloma growth in vitro and in vivo.
    Feng, Rentian
    Oton, Ana B.
    Patrene, Kenneth
    Anderson, Gulsum
    Mapara, Markus Y.
    Belani, Chandra
    Roodman, David
    Lentzsch, Suzanne
    BLOOD, 2006, 108 (11) : 153A - 154A
  • [35] The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage
    Feng, Rentian
    Oton, Ana
    Mapara, Markus Y.
    Anderson, Guelsuem
    Belani, Chandra
    Lentzsch, Suzanne
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (03) : 385 - 397
  • [36] Novel Heat Shock Protein 90 Inhibitor NVP-AUY922 Synergizes With the Histone Deacetylase Inhibitor PXD101 in Induction of Death of Anaplastic Thyroid Carcinoma Cells
    Kim, Si Hyoung
    Kang, Jun Goo
    Kim, Chul Sik
    Ihm, Sung-Hee
    Choi, Moon Gi
    Yoo, Hyung Joon
    Lee, Seong Jin
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (02): : E253 - E261
  • [37] Effects of a novel histone deacetylase inhibitor, PXD101, when used as monotherapy or in combination with bortezomib on tumor growth in mouse models of human multiple myeloma.
    Campbell, Richard A.
    Sanchez, Eric
    Chen, Haiming
    Turker, Lauren
    Trac, Olivia
    Li, Mingjie
    Shalitin, Dror
    Gordon, Melinda S.
    Pang, Shen
    Bonavida, Benjamin
    Said, Jonathan
    Jeffers, Michael
    Qian, Xiaozhong
    Lichenstein, Henri S.
    Berenson, James R.
    BLOOD, 2006, 108 (11) : 993A - 993A
  • [38] Gene expression screen in cell panel selected for varying sensitivity towards the histone deacetylase inhibitor (HDACi) PXD101 reveals potential predictors of HDACi sensitivity
    Dejligbjerg, Marielle
    Christensen, Ib Jarle
    Grauslund, Morten
    Jensen, Peter B.
    Sehested, Maxwell
    APMIS, 2007, 115 (03) : 287 - 287
  • [39] Phase II multicenter trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) for patients (pts) with relapsed ovarian cancer
    Finkler, Neil J.
    Dizon, Don
    Micha, John
    Braly, Patricia
    Lassen, Ulrik
    Sngelholm, S. A.
    Glasspool, Rosalind
    Crowley, Elizabeth
    Li, Shu-Xia
    Buhl-Jensen, Peter
    Penson, Richard
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3599S - 3599S
  • [40] Nuclear factor-κB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101
    Duan, Jianming
    Friedman, Jay
    Nottingham, Liesi
    Chen, Zhong
    Ara, Gulshan
    Van Waes, Carter
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (01) : 37 - 50
12345